ANI Pharmaceuticals/ANIP

$60.25

1.89%
-
1D1W1MYTD1YMAX

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company that serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceuticals, including for diseases with unmet medical needs. The Company is focused on developing and manufacturing niche oncology products (anti-cancer). It has a commercial portfolio of over 111 products with a variety of indications and a portfolio of pipeline products. The Company owns the facility, which includes oral solid dose and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space. It also owns a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products. The Company has four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey and one is located in Oakville, Ontario.

Ticker

ANIP

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Nikhil Lalwani

Employees

600

Headquarters

Baudette, United States

ANIP Metrics

BasicAdvanced
$1.21B
Market cap
118.30
P/E ratio
$0.50
EPS
0.76
Beta
-
Dividend rate

What the Analysts think about ANIP

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
15.77% upside
High $73.00
Low $66.00
$60.25
Current price
$69.75
Average price target

ANIP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
7.51% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$131.8M
-40.98%
Net income
$9.9M
30.26%
Profit margin
7.51%
120.88%

ANIP Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 50.59%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.76
$1.17
$1.28
$1.27
-
Expected
$0.67
$0.35
$0.68
$0.84
$0.86
Surprise
13.1%
231.91%
88.93%
50.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ANI Pharmaceuticals stock

Buy or sell ANI Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing